TP Miller

Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy.

William S. Dalton, Thomas M. Grogan, Paul S. Meltzer et al. · Journal of Clinical Oncology · 1989 · 560 citations

Immunology, Continuous Infusion Verapamil, Pathology +17

P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil.

TP Miller, Thomas M. Grogan, William S. Dalton et al. · Journal of Clinical Oncology · 1991 · 385 citations

Pathology, Pharmacotherapy, Verapamil Results +16

Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: the Southwest Oncology Group experience.

Dennis O. Dixon, Barbara A. Neilan, Siân Jones et al. · Journal of Clinical Oncology · 1986 · 362 citations

Cancer Management, Pathology, Pharmacotherapy +17

A clinical analysis of two indolent lymphoma entities: mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories): a Southwest Oncology Group study

R I Fisher, Steve Dahlberg, BN Nathwani et al. · Blood · 1995 · 347 citations · Full text

Prognostic significance of the Ki-67-associated proliferative antigen in aggressive non-Hodgkin's lymphomas: a prospective Southwest Oncology Group trial

TP Miller, TM Grogan, Steve Dahlberg et al. · Blood · 1994 · 238 citations · Full text